AFFYMAX INC (NASDAQ: AFFY)





$20.26 0.18 (0.90%)
Real-time 12:00:00 AM ET
Turn On
KEY STATS
52-Week High Price
25.64
52-Week Low Price
11.79
Avg Volume (3 Mo.)
0.00 M
Market Cap
0.38 B
P/E Ratio (TTM)
1.3
Diluted EPS (TTM)
-4.72
Shares
19.12 M
Dividend Rate ($) / (%)
0.00/0.00
67%
33%
You need to upgrade your Flash Player to view the graph.
View by Date Range:
12 Mo. Price Change : 33% - AFFY has outperformed the S&P 500 by 7%
SIMILAR COMPANIES
NameCurrent Price - Today's ChangeMarket Cap
OPKO HEALTH INC (OPK) $1.68 -  $0.01(0.59%)0.41 B
ENZON PHARMACEUTICALS (ENZN) $9.04 -  $0.04(0.44%)0.41 B
USANA HEALTH SCIENCE INC (USNA) $25.94 -  $0.13(0.50%)0.40 B
MEDICINES CO THE (MDCO) $7.66 -  $0.25(3.37%)0.40 B
QUIDEL CORP (QDEL) $12.63 -  $0.35(2.70%)0.39 B
FACET BIOTECH CORP (FACT) $15.77 -  $0.31(2.01%)0.39 B
PRESTIGE BRANDS HOLDINGS (PBH) $7.38 -  $0.18(2.50%)0.38 B
MAP PHARMACEUTICALS INC (MAPP) $14.98 -  $0.05(0.33%)0.37 B
IMMUNOGEN INC (IMGN) $6.42 -  $0.07(1.10%)0.37 B
ZYMOGENETICS INC (ZGEN) $5.05 -  $0.07(1.37%)0.36 B
STOCK ANALYSIS
Stock Analysis
Top 5 Volume Stocks For September 19 (AEC)
A look at five of the most active stocks in the market by midday, with a focus on Associated Estates Realty.
AFFY RELATED HEADLINES
arrow
Healthcare Stocks Galore
<ul> <li>Clarient's breast cancer technology for treatment</li> <li>Biomeds brain cancer drug in Phase III</li> <li>Medarexs 6 clinical candidates for '09 and '10</li> </ul>

Wall Street Media 12/11/2008
arrow
Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program

At BusinessWire 11/20/2008
arrow
Today's Batch of Biotechs
<ul> <li>Intuitive Surgical puts robotic machines in hospitals</li> <li>A new drug to help MS patients improve walking ability</li> <li>Growth for Greatbatch</li> <li> Varian's proton therapy machine</li> </ui>

Wall Street Media 11/19/2008
arrow
Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)
Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)

At BusinessWire 11/17/2008
arrow
Affymax to Present at Lazard Capital Markets Conference
Affymax to Present at Lazard Capital Markets Conference

At BusinessWire 11/13/2008
arrow
Affymax to Webcast Analyst and Investor Event on November 20, 2008
Affymax to Webcast Analyst and Investor Event on November 20, 2008

At BusinessWire 11/13/2008
Stock Simulator- Free Account
Chart Advisor- Free Report
Sponsored Links
COLOSIM2